Efficacy News and Research

RSS

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces today further positive results from the phase 2b PILLAR study of TMC435 in treatment-naive patients with hepatitis C virus genotype-1.

22 Feb 2011

GE Healthcare, CDC collaborate to explore efficacy of actionable health alerts

After a full year of feasibility studies, the Centers for Disease Control and Prevention is taking a significant step toward providing public health information at the point-of-care. CDC is collaborating with GE Healthcare, a unit of General Electric Company, to explore the efficacy of actionable health alerts, delivered instantly to a physician's electronic medical record.

21 Feb 2011

Investigational heart valve implanted in patient through small puncture hole in leg

Physicians at the Methodist DeBakey Heart & Vascular Center in Houston implanted a new investigational heart valve in a patient through a small puncture hole in the leg.

21 Feb 2011

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.

21 Feb 2011

Mouse model could help develop new classes of antidepressant drugs

The most widely prescribed antidepressants - medicines such as Prozac, Lexapro and Paxil - work by blocking the serotonin transporter, a brain protein that normally clears away the mood-regulating chemical serotonin. Or so the current thinking goes.

21 Feb 2011

Proper wound care may treat skin infections effectively than antibiotics in children with MRSA

When it comes to curing skin infected with the antibiotic-resistant bacterium MRSA, timely and proper wound cleaning and draining may be more important than the choice of antibiotic, according to a new Johns Hopkins Children's Center study. The work is published in the March issue of Pediatrics.

21 Feb 2011

New study: Venus White Pro whitens teeth up to 8.4 shades with virtually no sensitivity

Heraeus Kulzer, LLC, the leader in advancing dental esthetics and overall dental wellbeing, announced today the results of a new study that demonstrates that Venus White Pro whitens teeth up to 8.4 shades with virtually no sensitivity.

21 Feb 2011

QRxPharma granted FDA pre-NDA meeting, further phase II data released

QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today the granting of a pre-New Drug Application (NDA) meeting with the United States Food and Drug Administration (FDA) and successful completion of its third pivotal Phase 3 registration trial (study 009) for immediate-release MoxDuo.

20 Feb 2011

Experts caution against dangers of inflated expectations of genomic medicine

In the ten years since the human genetic code was mapped, expectations among scientists, health care industry, policy makers, and the public have remained high concerning the promise of genomics research for improving health.

19 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

FDA recognizes safety and efficacy of True Results LAP-BAND device

The True Results team of gastric band surgeons and medical weight loss experts is pleased the U.S. Food and Drug Administration has recognized the long-standing safety and effectiveness record of the LAP-BAND System.

19 Feb 2011

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

NovaBay Pharmaceuticals, Inc., a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has been ranked seventh in the biotech industry in Fast Company's annual list of the world's most innovative companies in 2011.

19 Feb 2011

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

Australian health care company Prima BioMed Ltd announced today that there has been an agreement for strategy and design of the Phase III clinical registration trial for the CVac™ immunotherapy therapeutic ovarian cancer vaccine.

19 Feb 2011

New tuberculosis vaccine provides better protection

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.

19 Feb 2011

EGS publishes three clinical studies on TIF procedure over past four months

EndoGastric Solutions, the leader in the emerging field of Natural Orifice Surgery (NOS), announced that three clinical studies on transoral fundoplication have been published over the past four months.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

TI Pharma launches new research project on stem cell transplant

Top Institute Pharma is today launching a new research project that should make stem cell transplants more successful. A stem cell transplant is usually performed on adults with acute leukemia.

18 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.

18 Feb 2011

Efficacy News and Research

Positive results from TMC435 phase 2b PILLAR study in treatment-naive patients with HCV

GE Healthcare, CDC collaborate to explore efficacy of actionable health alerts

Investigational heart valve implanted in patient through small puncture hole in leg

Advancell announces positive results from Acadra clinical study in Chronic Lymphocytic Leukemia

Mouse model could help develop new classes of antidepressant drugs

Proper wound care may treat skin infections effectively than antibiotics in children with MRSA

New study: Venus White Pro whitens teeth up to 8.4 shades with virtually no sensitivity

QRxPharma granted FDA pre-NDA meeting, further phase II data released

Experts caution against dangers of inflated expectations of genomic medicine

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

FDA recognizes safety and efficacy of True Results LAP-BAND device

Fast Company ranks NovaBay 7th in biotech industry in 2011 annual list of world's most innovative companies

EMA grants Prima BioMed Scientific Advice for CVac ovarian cancer vaccine Phase III trial

New tuberculosis vaccine provides better protection

EGS publishes three clinical studies on TIF procedure over past four months

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

TI Pharma launches new research project on stem cell transplant

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

Revolutionizing Life Science: An Interview with SCIEX on ASMS, the SCIEX 7500+ System, and AI-Driven Quantitation

From Discovery Biology to ELRIG Chair

Breathing New Life into Diagnostics: Plasmion's SICRIT Technology

Latest News